Black Diamond Therapeutics Inc (BDTX)

[FACT-MASTER]

Usually, material data of a trial is released to the public (8-K) prior to being used in a presentation. At times a day before or at times even on the same day as the presentation.

I don't see any events past this Friday's Jeffries Conference on the BDTX website, so it would be good to ask about the upcoming agenda for Events/Presentations for the rest of 2023.

https://investors.blackdiamondtherapeutics.com/events-presentations#target-1

I'm not 100% sure, however, imo, the logical course for providing data would be the NSCLC and GBM monotherapy data from the 2 original cohorts.

Here is a side by side of the January 26/23 study and the March 28/23 study - see arms and interventions
https://clinicaltrials.gov/ct2/history/NCT05256290?A=11&B=12&C=Side-by-Side#StudyPageTop

imo, data from the 2 original cohorts, may provide insight into the reason why the third cohort ( combo with SOC Temozolomide) was added.

In addition, since GBM is a serious condition requiring urgent clinical intervention, i would also be watching at the Jefferies conference for any language management might use regarding any of the FDA expedited programs and/or the FDA RTOR Program( if still available). Of course that info can come out in a PR at
anytime.

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics

Hopefully the recent positive stock performance is reflective of upcoming positive clinical data.